Dr. Cohen on Immunotherapy Combinations in Head and Neck Cancer

Video

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Combinations that incorporate IDO inhibitors, STAT-3 inhibitors, and anti-KIR monoclonal antibodies, are doubling and even tripling response rates in patients with head and neck cancer, says Cohen.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,